Cargando…
免疫检查点抑制剂相关皮肤不良反应诊治建议
Immune checkpoint inhibitors (ICIs) represent a major breakthrough in cancer therapy. Immune-related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Dermatologic toxicities appear to be one of the most prevalent irAEs. The most common symptoms are maculopap...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817433/ https://www.ncbi.nlm.nih.gov/pubmed/31650946 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.10.06 |
| _version_ | 1783463418495238144 |
|---|---|
| collection | PubMed |
| description | Immune checkpoint inhibitors (ICIs) represent a major breakthrough in cancer therapy. Immune-related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Dermatologic toxicities appear to be one of the most prevalent irAEs. The most common symptoms are maculopapular rash and pruritus. Serious dermatologic AEs, including Stevens-Johnson syndrome and toxic epidermal necrolysis, are rare. In this review, we summarized guidelines of management of immunotherapy-related toxicities and case reports, and proposed treatment recommendation. |
| format | Online Article Text |
| id | pubmed-6817433 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-68174332019-11-12 免疫检查点抑制剂相关皮肤不良反应诊治建议 Zhongguo Fei Ai Za Zhi 免疫检查点抑制剂专题 Immune checkpoint inhibitors (ICIs) represent a major breakthrough in cancer therapy. Immune-related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Dermatologic toxicities appear to be one of the most prevalent irAEs. The most common symptoms are maculopapular rash and pruritus. Serious dermatologic AEs, including Stevens-Johnson syndrome and toxic epidermal necrolysis, are rare. In this review, we summarized guidelines of management of immunotherapy-related toxicities and case reports, and proposed treatment recommendation. 中国肺癌杂志编辑部 2019-10-20 /pmc/articles/PMC6817433/ /pubmed/31650946 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.10.06 Text en 版权所有©《中国肺癌杂志》编辑部2019 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
| spellingShingle | 免疫检查点抑制剂专题 免疫检查点抑制剂相关皮肤不良反应诊治建议 |
| title | 免疫检查点抑制剂相关皮肤不良反应诊治建议 |
| title_full | 免疫检查点抑制剂相关皮肤不良反应诊治建议 |
| title_fullStr | 免疫检查点抑制剂相关皮肤不良反应诊治建议 |
| title_full_unstemmed | 免疫检查点抑制剂相关皮肤不良反应诊治建议 |
| title_short | 免疫检查点抑制剂相关皮肤不良反应诊治建议 |
| title_sort | 免疫检查点抑制剂相关皮肤不良反应诊治建议 |
| topic | 免疫检查点抑制剂专题 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817433/ https://www.ncbi.nlm.nih.gov/pubmed/31650946 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.10.06 |
| work_keys_str_mv | AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānpífūbùliángfǎnyīngzhěnzhìjiànyì AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānpífūbùliángfǎnyīngzhěnzhìjiànyì AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānpífūbùliángfǎnyīngzhěnzhìjiànyì AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānpífūbùliángfǎnyīngzhěnzhìjiànyì AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānpífūbùliángfǎnyīngzhěnzhìjiànyì AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānpífūbùliángfǎnyīngzhěnzhìjiànyì AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānpífūbùliángfǎnyīngzhěnzhìjiànyì AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānpífūbùliángfǎnyīngzhěnzhìjiànyì AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānpífūbùliángfǎnyīngzhěnzhìjiànyì AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānpífūbùliángfǎnyīngzhěnzhìjiànyì |